GlaxoSmithKline Confirms Receipt Of FDA Letter On Regulatory Reporting
GlaxoSmithKline confirmed it has received a warning letter from the US Food and Drug Administration (FDA) related to reporting requirements for approved medicines. The letter follows a routine FDA inspection of GSK’s reporting processes conducted last year.
More: continued here